Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayer A G Ord (BAYZF)

Bayer A G Ord (BAYZF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 20.57
  • Price/Book 5.23
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.0000 +0.61%
on 02/27/26
58.3276 -15.48%
on 02/17/26
-5.5700 (-10.15%)
since 01/26/26
3-Month
35.2600 +39.82%
on 11/28/25
58.3276 -15.48%
on 02/17/26
+14.0250 (+39.76%)
since 11/26/25
52-Week
20.9900 +134.87%
on 04/09/25
58.3276 -15.48%
on 02/17/26
+25.6400 (+108.37%)
since 02/27/25

Most Recent Stories

More News
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

  225 Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration-resistant prostate cancer (mCRPC)...

BAYRY : 12.3000 (-0.08%)
BAYZF : 49.3000 (-1.53%)
BAYN : 0.0100 (unch)
Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

Final results for the key secondary endpoint of overall survival (OS) from the PEACE-3 trial will be presented by the European Organization for Research and Treatment of Cancer (EORTC) coalition as an...

BAYRY : 12.3000 (-0.08%)
BAYZF : 49.3000 (-1.53%)
BAYN : 0.0100 (unch)
Bayer Alleges J&J’s Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J’s ERLEADA

Bayer files false advertising suit against J&J and Janssen Biotech Lawsuit seeks preliminary and permanent injunctions in addition to damages. This...

BAYRY : 12.3000 (-0.08%)
BAYZF : 49.3000 (-1.53%)
BAYN : 0.0100 (unch)
Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month

This February, the brand continues its See Your Risks initiative by challenging denial and bringing unseen heart health risk factors into view.

BAYRY : 12.3000 (-0.08%)
BAYZF : 49.3000 (-1.53%)
BAYN : 0.0100 (unch)
Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significantly less likely to suffer a secondary stroke compared...

BAYRY : 12.3000 (-0.08%)
BAYZF : 49.3000 (-1.53%)
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign

‘Highlights REAL’ aims to spark vital conversations about advanced prostate cancer and educate about the importance of treatment management

BAYRY : 12.3000 (-0.08%)
BAYZF : 49.3000 (-1.53%)
BAYN : 0.0100 (unch)
Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada

Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada’s leadership in canola innovation by establishing a cutting-edge canola innovation centre. Located...

BAYRY : 12.3000 (-0.08%)
BAYZF : 49.3000 (-1.53%)
BAYN : 0.0100 (unch)
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention

Findings from OCEANIC-STROKE, including the main results and a prespecified subgroup analysis, will be presented for the first time during two late-breaking sessions at the International Stroke Conference...

BAYRY : 12.3000 (-0.08%)
BAYZF : 49.3000 (-1.53%)
Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases

Not intended for UK Media Collaboration spans across various indications with an initial focus on cardiovascular and kidney diseases, addressing areas of significant...

BAYRY : 12.3000 (-0.08%)
BAYZF : 49.3000 (-1.53%)
BAYN : 0.0100 (unch)
Bayer Accelerates Pharma Growth on High-Value Portfolio

Bayer is successfully executing on an ambitious growth strategy Five pivotal approvals worldwide in 2025 underscore a landmark year of strategic execution Bayer will...

BAYRY : 12.3000 (-0.08%)
BAYZF : 49.3000 (-1.53%)
BAYN : 0.0100 (unch)

Business Summary

Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third-largest in the world. HealthCare subgroup...

See More

Key Turning Points

3rd Resistance Point 50.2460
2nd Resistance Point 49.9368
1st Resistance Point 49.6184
Last Price 49.3000
1st Support Level 48.9908
2nd Support Level 48.6816
3rd Support Level 48.3632

See More

52-Week High 58.3276
Last Price 49.3000
Fibonacci 61.8% 44.0646
Fibonacci 50% 39.6588
Fibonacci 38.2% 35.2530
52-Week Low 20.9900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar